ELVN

Enliven Therapeutics is a clinical-stage precision oncology company focused on developing small molecule kinase inhibitors for the treatment of cancer. The company's lead program targets patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) harboring specific genetic mutations. Enliven's pipeline includes novel BCR-ABL1 tyrosine kinase inhibitors designed to overcome resistance mechanisms that limit the effectiveness of current therapies. The company's precision medicine approach aims to develop therapies matched to specific patient populations based on genetic biomarkers.